基本信息
浏览量:176
职业迁徙
个人简介
Désiré Collen holds a M.D. degree (1968) and Ph.D. degree in Chemistry (1974) from Katholieke Universiteit Leuven, Belgium. He served as Director of the Molecular Cardiovascular Medicine Group (comprising the Center for Molecular and Vascular Biology of the Katholieke Universiteit Leuven, and the Vesalius Research Center of the Flanders Institute for Biotechnology) in Leuven, Belgium until September 2008. He has research interests in translational research in biopharmaceutical drug development. His team initially developed t-PA, still the most effective drug for thrombolytic therapy of acute myocardial infarction. Dr. Collen has co-authored over 650 research papers and has received four honorary doctorates and several scientific awards including the Francqui Prize (Belgium), the Prix Louis Jeantet de Médecine (Switzerland), the Bristol-Myers-Squibb award for Cardiovascular Research (USA), and the Health Prize of the Interbrew-Baillet Latour Fund (Belgium) (jointly with P. Carmeliet). He was the Founder of and until August 2008 Chief Executive Officer of ThromboGenics, NV, a biopharmaceutical drug development company listed on Euronext Brussels. Till beginning of December 2013 he was the Chairman of the Board of ThromboGenics NV.
研究兴趣
论文共 145 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn